• Riccardo Bixio, Sara Bindoli, Andrea Morciano, Roberto Padoan, Federico Aldegheri, Francesca Mastropaolo, Eugenia Bertoldo, Denise Rotta, Matteo Appoloni, Giovanni Orsolini, Davide Gatti, Giovanni Adami, Ombretta Viapiana, Maurizio Rossini, Paolo Sfriso, and Angelo Fassio.
• Rheumatology Unit, Department of Medicine, University of Verona, P.le L.A. Scuro 10, 37134, Verona, Italy. riccardo.bixio@univr.it.
• Intern Emerg Med. 2024 Nov 1; 19 (8): 233123452331-2345.

AbstractVEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic) syndrome is characterized by heterogeneous clinical manifestations. Due to the inflammatory nature of this condition, 18-FDG-PET (18-fluorodeoxyglucose-positron emission tomography) might be used to diagnose and monitor the disease. However, no data are available about the most common findings of PET imaging in this disease. For this reason, we summarised all the available reports of patients with VEXAS who underwent at least one PET scan and described 8 additional patients' PET from our centres. Overall, we described 35 patients' PET findings. All patients were male, with a median age of 70 years. The most frequent hypermetabolic sites on PET scans were the bone marrow (77.1%), lymph nodes (35.3%), lungs (28.6%), spleen and large vessels (22.9%), and cartilage (20%). Six patients underwent a PET scan 2.7 ± 1.5 years before VEXAS diagnosis, showing nonspecific uptake in the bone marrow. Four patients had a follow-up PET scan, showing a decrease or a disappearance of the previously identified hypermetabolic areas. In conclusion, although no specific uptake site has been found for VEXAS syndrome, PET imaging could help detect inflammatory foci that are not clinically evident. In addition, high metabolic activity in bone marrow might precede the clinical onset of the disease, shedding light on the pathogenesis of VEXAS.© 2024. The Author(s).

17 keywords...

hide…